International Journal of Thyroidology

Table. 1.

Table. 1.

The summary of clinical characteristics of lenvatinib induced pneumothorax in the literature with our cases

Age/sex Cancer type Surgery Lung metastasis Other distant metastases Cavitations of metastatic lung nodules after lenvatinib Pneumothorax

Symptom Time from lenvatinib initiation Bilaterality Lenvatinib dose at the moment of pulmonary event Treatment Lenvatinib therapy Disease response to lenvatinib
Kazzaz et al.6) 73/M ATC TT + Mediastinal lymph nodes + Mild dyspnea 2 months Bilateral NA Chest tubing and chemical pleurodesis Temporary cessation and restart with lower dose Progression during lenvatinib withhold.
Yamazaki et al.7) 63/M ATC None + NA + None 34 days Unilateral 20 mga Chest tubing Maintenance SD
Lee et al.27) 77/M ATC None + None Dyspnea 50 days Bilateral 24 mga Chest tubing and wedge resection Temporary cessation and restart with lower dose (20 mg) SD → patient died before 1 month after lenvatinib restarting
Kawanishi et al.30) 71/M HCC None + None + Dyspnea, back pain 2 months Unilateral 12 mga Thoracoscopic wedge resection and chest tubing Cessation PD → patients died ten days after discharge
Our case 1 (case 2) 49/F ATC None + Bone, liver + None 353 days Unilateral 14 mga Supportive care Temporary cessation and restart at the same dose PD
Our case 2 (case 3) 80/F PDTC TT + Bone + None 292 days Unilateral 10 mga Supportive care Maintenance SD

ATC: anaplastic thyroid cancer, HCC: hepatocellular carcinoma, NA: not applicable, PD: progressive disease, PDTC: poorly differentiated thyroid cancer, SD: stable disease, TT: total thyroidectomy

aThe lenvatinib dose at the moment of pulmonary event is the same as the median daily dose before the event.

Int J Thyroidol 2022;15:42-8
© 2022 Int J Thyroidol